Company record
Ajanta Pharma USA Inc
0 FDA warning letters since 2023 and 4 recalls in the last 12 months.
Get an email the day FDA posts anything new about Ajanta Pharma USA Inc.
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Oct 7 | Class II | Ajanta Pharma USA Inc Drug |
Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02 Failed Dissolution Specifications: below specification |
| Sep 16 | Class III | Ajanta Pharma USA Inc Drug |
Fluphenazine Hydrochloride Tablets, USP, 1mg, 100-count bottles, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-255-01. Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability. Result: 1.1 percent. Spec: 1.0 percent. |
| Jul 1 | Class II | Ajanta Pharma USA Inc Drug |
Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, Manufactured by: Ajanta Pharma Limited, India, Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807, NDC 27241-120-04. CGMP Deviations |
| Jun 24 | Class II | Ajanta Pharma USA Inc Drug |
Aripiprazole Tablets USP, Rx only, 30 mg, 30 tablets, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-056-03. Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg. |